Literature DB >> 6956782

Analysis of human leukemia/lymphoma cell lines with monoclonal antibodies BA-1, BA-2 and BA-3.

T LeBien, J Kersey, S Nakazawa, K Minato, J Minowada.   

Abstract

A panel of monoclonal antibodies (BA-1, BA-2 and BA-3) were made against the pre-B acute lymphoblastic leukemia (ALL) cell line NALM-6. BA-3 binds to the 100,000 mol. wt common ALL antigen (gp100/CALLA), BA-2 binds to a 24,000 mol, wt (p24) cell surface structure and BA-1 binds to a currently undefined antigen. These antibodies were analysed for their reactivity with 67 human leukemia/lymphoma cell lines. The cell lines studied included T ALL, non-T ALL, surface immunoglobulin+ leukemias/lymphomas, and myeloid/monocytoid leukemias. The results indicate that all three antibodies react primarily (but not exclusively) with malignant cells early in B cell development. This pattern of reactivity was similar to previous results obtained with fresh, non-cultured malignant cells. BA-1, BA-2 and BA-3 are useful tools for analysing the developmental options of normal lymphoid cells and for "cleaning up" leukemia/lymphoma cells in selected cases of autologous bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6956782     DOI: 10.1016/0145-2126(82)90091-1

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  Lymphocyte subsets in the peripheral blood of patients with multiple myeloma and benign monoclonal gammopathy.

Authors:  F Herrmann; A Lochner; B Jauer; G Sieber; H Rühl
Journal:  Klin Wochenschr       Date:  1983-08-15

2.  Construction of an antigenic map for human B-cell precursors.

Authors:  G B Melink; T W LeBien
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

3.  Immunoglobulin mu-chain gene rearrangement in a patient with T cell acute lymphoblastic leukemia.

Authors:  K Ha; M Minden; N Hozumi; E W Gelfand
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

4.  Different stages of B cell differentiation in non-T acute lymphoblastic leukemia.

Authors:  R Foa; N Migone; M Saitta; M T Fierro; M C Giubellino; P Lusso; L Cordero di Montezemolo; R Miniero; F Lauria
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

5.  Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.

Authors:  H M Lokhorst; S E Boom; B J Bast; P J Peters; T F Tedder; J Gerdes; E Petersen; R E Ballieux
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

6.  Diagnostic specificity of the monoclonal anti-CALLA antibody VIL-A1 in leukemia and malignant lymphoma.

Authors:  W Knapp; D Lutz; P Bettelheim; T Radaszkiewicz; O Majdic; H Gadner
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Expression of the common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease.

Authors:  L K Trejdosiewicz; G Malizia; J Oakes; M S Losowsky; G Janossy
Journal:  J Clin Pathol       Date:  1985-09       Impact factor: 3.411

8.  Augmentation of mixed lymphocyte response. Stimulatory activity by phorbol ester.

Authors:  J Okamura; M Letarte; E W Gelfand
Journal:  J Clin Immunol       Date:  1984-05       Impact factor: 8.317

9.  Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen.

Authors:  J Cossman; L M Neckers; W J Leonard; W C Greene
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Comparative studies between a new human rhabdomyosarcoma cell line, JR-1 and its tumour of origin.

Authors:  J Clayton; J R Pincott; J A van den Berghe; J T Kemshead
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.